SOFTATHOME
26.9.2018 09:02:12 CEST | Business Wire | Press release
SoftAtHome, the software company dedicated to the digital home, and V3D, a leading independent software vendor expert on Telecom data analytics for carrier network operators, announced today the signing of an acquisition agreement.
With SoftAtHome acquiring V3D, the company will be able to deliver a full range of solutions around “analytics for Quality of Experience” for its fixed and mobile operator clients, by relying on the millions of data points collected by V3D.
Thanks to both companies’ expertise, skills and solutions, Carrier Network Operators will benefit from a global value proposition on improving Customer Experience on their fixed and mobile networks.
David VIRET-LANGE, Chief Executive Officer of SoftAtHome, commented: “In an increasingly digital world, consumers expect seamless connectivity with their mobile and tablets wherever they are. Quality of Experience will be naturally measured by the same solutions. The V3D solution portfolio and expertise on mobile and fixed network and the skills of SoftAtHome on Wi-Fi and networking will allow our companies to provide the best-in-class Data Analytics and monitoring tools that will help operators deliver an unmatched Quality of Experience for their customers.”
Philippe VIAL-GRELIER, Co-Founder and Managing Director of V3D, added: “We are pleased to join SoftAtHome and combine our skills to facilitate end-to-end access to the entire Customer Experience value chain for carrier network operators. This merger is part of our desire to strengthen our position in the Telecom data analytics for both fixed and mobile markets.”
About SoftAtHome
SoftAtHome creates software for operators
to deploy services with the best user experience for connectivity, pay
TV, Home Networking and Smart Home products. SoftAtHome products are
deployed with major operators in over 20 million homes over 18
countries. The company based in France and Belgium is still growing with
over 250 employees mainly in software development. We are regularly
opening new offices to support our customers. Offices are already in
half a dozen European capitals as well as in Dubai, Singapore and
Toronto. www.softathome.com
About V3D
Specialized in mobile and fixed network
technologies, V3D Solutions enable carrier network operators to monitor
the true network Quality of Experience (QoE) straight from the
subscribers’ perspective. This approach to traditional measurement
methods of network performance offers technical and business benefits to
various departments of an operator, from CEM & Marketing to Network
Operations or Customer Care.
V3D product portfolio focuses on
customer experience and carrier network service performance. The EQual
One solution is based on a combination of Device Quality Agents (DQA)
deployed on commercial devices and a powerful server interacting
over-the-air with the DQAs and potentially integrated with existing
systems. V3D headquarters are based in Lyon, France. For more
information, visit: www.v3d.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20180926005082/en/
Contact:
Media SoftAtHome Marta TWARDOWSKA, M: +31 621-184-585 e: press@softathome.com T: @SoftAtHome www.softathome.com or V3D Hélène VALLEE, + 33 481 761 370 hvallee@v3d.fr press@v3d.fr www.v3d.fr
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom